Acuson Restakes its Claim in Ultrasound
After nine years and $350 million spent on R&D, Acuson launched two new products it believes will reestablish it as the company that sets the gold standard for ultrasound.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.